LAUSR

REFERENCES 1. Taher AT, Weatherall DJ, Cappellini MD. Thalassemia. Lancet. 2018; 391(10116):155-167. 2. Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassemia treatment: how will we manage this old disease with new therapies? Blood Rev. 2018;32(4):300-311. 3. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73. 4. Bou-Fakhredin R, Bazarbachi AH, Chaya B, Sleiman J, Cappellini MD, Taher AT. Iron overload and chelation therapy in non-transfusion dependent thalassemia. Int J Mol Sci. 2017;18(12):2778. 5. Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2011;86(1):92-95. 6. Amid A, Leroux R, Merelles-Pulcini M, et al. Factors impacting quality of life in thalassemia patients; results from the intercontinental collaborative study. Blood. 2016;128:3633.